Kontafarma China Holdings (HKSE:01312) Beta: 0.4182 (As of Aug. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Kontafarma China Holdings Beta?

Kontafarma China Holdings HKSE:01312 +3.45% Beta is 0.4182 as of Aug. 07, 2026. The stock has 3 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-08-07), Kontafarma China Holdings's Beta is 0.4182.


Kontafarma China Holdings  (HKSE:01312) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Kontafarma China Holdings Beta Related Terms


Kontafarma China Holdings Beta Historical Data

* Premium members only.

The historical data trend for Kontafarma China Holdings's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kontafarma China Holdings Beta Chart

Kontafarma China Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.56 0.75 0.27 0.38 0.13

Kontafarma China Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 0.32 0.38 0.33 0.13

HKSE:01312 vs ZTS: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kontafarma China Holdings's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kontafarma China Holdings Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kontafarma China Holdings's Beta distribution charts can be found below:

* The bar in red indicates where Kontafarma China Holdings's Beta falls into.



Kontafarma China Holdings Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.4182 mean?
Kontafarma China Holdings (HKSE:01312) has a Beta of 0.4182 as of Aug. 07, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Kontafarma China Holdings and its competitors.
Is Kontafarma China Holdings' Beta too high?
Kontafarma China Holdings' current Beta is 0.4182.
How does Kontafarma China Holdings' Beta compare to ZTS?
Kontafarma China Holdings' Beta of 0.4182 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Kontafarma China Holdings and its competitors. Kontafarma China Holdings's current Beta is 0.4182. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kontafarma China Holdings stock overvalued right now?
Based on GuruFocus' analysis, Kontafarma China Holdings (HKSE:01312) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.04, compared to a current price of HK$0.03 — trading 25% below its estimated fair value. The current Beta is 0.4182. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Kontafarma China Holdings (HKSE:01312), the current Beta is 0.4182 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kontafarma China Holdings Business Description

Address 30 Harbour Road, Room 12A15-12A20, 12A Floor, Sun Hung Kai Centre, Wanchai, Hong Kong, HKG
Kontafarma China Holdings Ltd and its subsidiaries are principally engaged in the pharmaceutical and fitness business. The Group manufactures and sells prescription drugs, including chemical drugs, traditional Chinese medicine prescriptions, active pharmaceutical ingredients, and API intermediates in China, and operates fitness centres, provides fitness and health consultation services, and operates a franchise business for royalty fee income. Its segments are the pharmaceutical business, which generates maximum revenue, and the fitness business. The Group operates in Mainland China, Singapore, Taiwan, and other regions, with maximum revenue from Mainland China.